Company: KROS
Filing Date: 2025-05-09
Form Type: DEFA14A
Source: 0001104659-25-046272
Chunk: 3

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-09
Form: DEFA14A
Chunk 3
---
’ most advanced product candidate, elritercept (KER-050),
is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with
myelodysplastic syndrome and in patients with myelofibrosis.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Words such as “anticipates,” “believes,” “continue,” “expects,” “enable,”
“potential” and “will” or similar expressions are intended to identify forward-looking statements. Examples of
these forward-looking statements include statements concerning the intended benefits and outcome of the strategic review process, expected
cash runway, our continued collaboration with Takeda Pharmaceuticals. Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties
include, among others: whether the objectives of the strategic alternative review process will be achieved; the terms, structure, benefits
and costs of any strategic transaction; the timing of any transaction and whether any transaction will be consummated at all; the risk
that the strategic alternatives review and its announcement could have an adverse effect on the ability of the Company to retain and hire
key personnel and maintain relationships with partners, suppliers, employees, stockholders and other business relationships and on its
operating results and business generally; the risk the strategic alternatives review could divert the attention and time of the Company’s
management; the risk of any unexpected costs or expenses resulting from the review; the risk of any litigation relating to the review;
the risk that circumstances surrounding or leading up to our 2025 Annual Meeting may change; Keros’ limited operating history and
historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product
candidates; Keros’ dependence on the success of its product candidates, cibotercept, KER-065 and elritercept; that Keros may be
delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar
uses; Keros’ ability to obtain, maintain and protect its intellectual property; and Keros’ dependence on third parties in
connection with manufacturing, clinical trials and preclinical studies.

These